The main focus of the Genomics Shared Resource (GSR) is to provide expertise and comprehensive service in the area of microarray- and next-generation sequencing (NGS)-based genomics research in both a highly accessible and cost-effective manner for Cancer Center members. The GSR, originally named as the Gene Expression Resource, has been an active Shared Resource in the Cancer Center since the first application for NCI designation in 2001. Since then, we have expanded our portfolio of services to encompass nearly every level of genomics ranging from analysis of cancer genomes with single-base resolution up through standard mRNA and miRNA expression profiling. These also include single nucleotide polymorphism genotyping, epigenomics, and analyses for transcript splice variants, fusion genes, and genomic instability. The GSR has strived to provide our researchers with direct access to the most contemporary genomic applications and state-of-the-art instrumentation. Towards this goal, we possess the capacity to perform profiling on most of the common commercially-available microarray platforms (e.g., Affymetrix, Agilent, lllumina) as well as custom-designed ones. Having recently acquired an lllumina Genome Analyzer llx NGS system, the GSR now also provides this exciting state-of-the-art profiling technology. Importantly, all of these applications can be utilized for translational research as a result of our development of optimized protocols for the analysis of samples from a broad range of sources and of extremely limited amounts. To complement these services and to help achieve productive outcomes from genomics experiments, the GSR also provides extensive data analysis and integrative bioinformatics support and routinely assists in the preparation of the appropriate sections of manuscripts and grant proposals. Taken together, the GSR provides a complete integrative and functional molecular profiling solution to the Cancer Center.
This resource provides leading technologies for the analysis of genes, gene expressions, and DNA-related, cellular material used in examining cancer cells and comparing them to normal cells to gain insights into the cellular processes, events, and materials implicated in cancer. Thus it improves the scientific quality of cancer research and ultimately the development of more effective cancer therapies.
|Zhang, Jin; Lucchesi, Christopher; Chen, Xinbin (2016) A new function for p53 tetramerization domain in cell fate control. Cell Cycle 15:2854-2855|
|Vinall, Ruth L; Tepper, Clifford G; Ripoll, Alexandra A Z et al. (2016) Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. Genes Cancer 7:86-97|
|Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2016) A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study. Leuk Lymphoma 57:2307-14|
|TachÃ©, VÃ©ronique; Bivina, Liga; White, Sophie et al. (2016) Lipoyltransferase 1 Gene Defect Resulting in Fatal Lactic Acidosis in Two Siblings. Case Rep Obstet Gynecol 2016:6520148|
|Lara, Joshua; Brunson, Ann; Keegan, Theresa H M et al. (2016) Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry. J Urol 196:1378-1382|
|Faisal, Farzana A; Sundi, Debasish; Tosoian, Jeffrey J et al. (2016) Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. Eur Urol 70:14-7|
|Dang, Julie H T; Chen Jr, Moon S (2016) Increasing Hepatitis B Testing and Linkage to Care of Foreign-Born Asians, Sacramento, California, 2012-2013. Public Health Rep 131 Suppl 2:119-24|
|Rowson-Hodel, Ashley R; Berg, Anastasia L; Wald, Jessica H et al. (2016) Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells. Cancer Lett 375:62-72|
|Zhao, Yong; Tu, Mei-Juan; Wang, Wei-Peng et al. (2016) Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep 6:26611|
|Monjazeb, Arta M; Kent, Michael S; Grossenbacher, Steven K et al. (2016) Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. Clin Cancer Res 22:4328-40|
Showing the most recent 10 out of 608 publications